Core Viewpoint - Hendi Pharmaceutical (301211.SZ) is currently experiencing a decline in stock price, with a closing price of 13.20 yuan and a market capitalization of 5.512 billion yuan, indicating it is in a state of share price drop since its IPO [1] Group 1: IPO Details - Hendi Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 22, 2021, with an initial public offering (IPO) of 60 million shares at a price of 25.80 yuan per share [1] - The total funds raised from the IPO amounted to 1.548 billion yuan, with a net amount of 1.401 billion yuan, exceeding the originally planned fundraising by 210 million yuan [1] - The company initially aimed to raise 1.19 billion yuan for various projects, including the production of 5,000 tons of ibuprofen raw materials and 1,200 tons of other raw materials [1] Group 2: Financial Announcements - On May 24, 2023, Hendi Pharmaceutical announced a stock bonus plan, proposing to increase the share capital by 2 shares for every 10 shares held, along with a pre-tax dividend of 4 yuan [2] - On August 1, 2025, the company announced another stock bonus plan, proposing to increase the share capital by 4.5 shares for every 10 shares held [3]
亨迪药业跌2.87% 2021年上市募15.48亿元